Get started

PFIZER

BULLISH IMPULSE IS COMING 💉✅PREVIOUSLY ON PFE We were expecting that A was broken and it's broken. ✅ WHERE WE ARE We have expected the drop to 43.27(Fib61.8). If the price is rejected around Fib61.8, we can expect the bullish impulsive wave. *As long as 37.96 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFELong
by waveslover
PFE Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NYSE:PFEShort
by hadimozayan
PFIZER Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NYSE:PFEShort
by hadimozayan
2
DROPPING WELL AS EXPECTED. READY FOR THE 3RD BOOST? 👁️ 💉✅PREVIOUSLY ON PFE We were expecting that A was broken and it's broken. ✅ WHERE WE ARE Because A is broken, it's confirmed that 47.50 is B. If so, we should recognize the C, at which bearish 5 waves would be formed after B. As of now, 43.27(Fib61.8) looks like the good long entry point to ride the next boost. *As long as 37.96 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFE
by waveslover
PFIZER: FUNDAMENTAL ANALYSIS + NEXT TARGET POINT ⚡️As you know, Pfizer's biggest product at the moment is the coronavirus vaccine, Comirnati. The company and its partner BioNTech expect it to bring in more than $33 billion this year. Meanwhile, Pfizer expects revenue from the coronavirus vaccine to account for 42% of the company's total revenue. The vaccine is certainly one good reason to buy stock in this major pharmaceutical giant. But there is another reason to buy Pfizer stock, and it has nothing to do with the COVID-19 vaccine. It is important to remember that Pfizer has a huge number of commercialized products, including seven blockbuster drugs. Earlier this month, one of them received good news - news that should prompt us to take a closer look at this pharmaceutical company's stock. Eliquis, the blood-thinning drug commercialized by Pfizer and its partner Bristol Myers Squibb, received a very important decision in the appeals court. The court upheld the original decision protecting the patents on this best-selling drug, including the drug's composition and formula. This means that the generic drugmaker will not be able to enter the market with a competing drug until April 2028. Pfizer and Bristol Myers will probably file another appeal, but after two courts have already ruled in their favor, one can be optimistic about their case. This is great news for Pfizer, given the revenue generated from the sale of the drug Eliquis. Last year, Pfizer reported more than $4.9 billion in revenue from the alliance and direct sales of the drug Eliquis. That's a 17% increase over the previous year. And this was during a pandemic when access to non-COVID health care was limited. Eliquis continues to be one of Pfizer's biggest drugs. In the second quarter of this year, Eliquis generated more than $1.4 billion in revenue. That's a 16% increase over the previous year, and Eliquis was Pfizer's second-largest drug after the coronavirus vaccine. Of course, generic competition will eventually lead to lower sales of this blockbuster drug. But the court ruling gives Pfizer seven years to develop products that can replace Eliquis as a major source of revenue. Pfizer has a lot of development going on. One of the most interesting candidates is an oral drug to treat the coronavirus. It would be a pill that people could take within days of the first symptoms, and it could be a game-changer and generate billions of dollars in revenue. Pfizer began Phase 2/3 trials in July and plans to present data in the fourth quarter. The company also recently began a Phase 3 trial of a vaccine candidate against respiratory syncytial infection. Currently, there is no vaccine against this common cause of severe respiratory disease. Should you buy Pfizer stock because of news about the Eliquis patent? It's not the only reason to buy the stock, but it's one great reason. Add to that the recurring earnings from the coronavirus program. And let's not forget the company's other blockbusters. Let's not forget the drugs and vaccines that could bring in a lot of revenue in the future. All of this together is a solid recipe for success over time. Pfizer stock is up 25% and is currently outperforming the S&P 500 Index. However, the stock is hardly reflective of all the positives now and in the future. They are trading at 11 times earnings estimates. By that measure, the stock is cheap today. Pfizer stock is far behind biotech players in the coronavirus vaccine space such as its own partner BioNTech and rival Moderna. You can't be sure that the situation will change. It's much easier to quickly raise the price of a company with less market value than a major pharmaceutical player. But over time, Pfizer has serious potential to increase revenues and profits -- and that should match the stock's rise. This month's news on the Eliquis patent is a huge step in the right direction.
NYSE:PFELong
by FOREXN1
4
PFE STILL MORE GAS IN THE TANKThis chart has been fairly predictable for the past year, however as we start to shape up the larger degree wave count, I've decided to alter this from an expanding diagonal to a typical impulse. The main thing shaping this is the action for wave 2 which appears to be a flat. Under this premise, we have subdivision of wave 3 underway. It appears to be an expanded third: triggering the 1.618 with evidence of another leg up to the 2.272 at $56. This is the primary trade at hand, as we target 15-20% gains here. This trade presents a 10:1 RR with a SL around $45.50 at the recent low for a 20% target. Wave 4 of 3 looks to be complete, hitting the 1.618 extension of A to B (see chart below). We have RSI testing the 70 which will be telling: if it can get into overbought territory, then it's indication of a trend reversal (as markets typically only go into overbought when bullish). Not pictured is the stacking bullish divergence for this wave 4. Another thing that stands out as evidence of wave 4 complete is that it was sharper than wave 2 of 3. By rule of alternation, we would expect this. Upon hitting this target near $56, we will reevaluate, likely close, and look for the next wave down. For now, I have a $45 level identified (w4 larger count) and a 2.618 target near $60 (w5 larger count) on the map. Remember: for extended wave 3s that approach the 2.0, we look for the next fib level near 2.618 for w5. These future targets are dependent on what happens here in this wave 3.
NYSE:PFELong
by warrenbudget
9
Pfizer here we go! Holding while price is green. 🚀🚀🚀Stocks trend. A lot. Much more than Forex. Pfizer is going parabolic while breaking all time high and $50, this could be the start of a big trend, or it might not. Let's look at a few examples starting with Pfizer. Clearly we see how with stocks we can make big multiples of our risk. Like 25R in stocks versus 10R in Forex (for example, reality is probably close to that) Zooming in the little impulses: I don't know how many "casuals" are interested in Pfizer, but it is a word billions of people know. We can look at Tesla & PonziStop: How about another one just to illustrate? So the question is, how to hold on but without giving back all profits? 1 solution is sell half once a stop is reached keep half with a much wider stop. Smooths out the PnL. And this is probably what I'll do. On a longer TF I'd look to add, here this is all a short term play, expecting the stock to go parabolic. I am at exactly 5 times my risk (counting spreads) as of writting this. Hasn't even been 2 weeks yet. Talk about a monster. This risk a monster correction too. Hopefully it warns before.
NYSE:PFELong
by MrRenev
4
PFIZER INC.:FUNDAMENTAL ANALYSIS+PRICE ACTION|NEXT TARGET|LONG🔔Earlier this month, Pfizer announced promising first-line results from a Phase 2b/3 trial testing the JAK inhibitor ritecitinib for the treatment of alopecia(baldness), suggesting that the drug could finally be approved to treat this autoimmune disease that causes hair loss. But as Jeff Little noted, "The FDA has recently been paying increased attention to the potential side effects of JAK inhibitors, which belong to a family of drugs called DMARDs (disease-modifying anti-rheumatic drugs)." Let's look at the results of the study, what the FDA's concerns mean for this drug and others like it, and whether pharmaceutical giant Pfizer has a chance to make a name for itself in the growing global market for alopecia medications. Pfizer's phase 2b/3 study of the drug ritlecitinib examined the drug's effect on alopecia treatment in a randomized clinical trial involving 719 patients. These patients were 12 years of age or older, had 50% or more scalp hair loss (as measured by the Severity of Alopecia Tool scale, or SALT), and had experienced a current episode lasting six months to 10 years. Pfizer remarked that a clinically meaningful proportion of patients who received 30 mg or 50 mg of ritlecitinib daily achieved less than 20% head hair loss on the SALT scale after 24 weeks of treatment opposed to placebo, consistent with the study's primary efficacy endpoint of improved head hair regrowth. According to Pfizer, the scientific basis for ritlecitinib is that the drug stops the body's immune system from attacking hair follicles, which is thought to contribute to hair loss in patients with alopecia. Despite the study's encouraging results, it's worth noting that ritlecitinib's path to FDA approval for the alopecia indication (or for vitiligo, rheumatoid arthritis, Crohn's disease, and ulcerative colitis, for that matter) will be even more thorough than usual because of its special class of drugs. Ritlecitinib belongs to the class of Janus kinase inhibitors, or JAK inhibitors, which have been under scrutiny by the FDA lately. As per Fierce Pharma, a post-marketing study of Pfizer's JAK-inhibitor Xeljanz revealed serious heart and cancer side effects when the study results were published at the beginning of the year. This urged the FDA to delay the potential approval of the JAK inhibitor back in February while the agency investigates further. Xeljanz was first approved by the FDA in 2012 to treat rheumatoid arthritis, or RA, an autoimmune disease that can cause joint pain and damage throughout the body. The drug was also approved by the FDA in 2017 to treat psoriatic arthritis and in 2018 to treat ulcerative colitis. Although no serious adverse cardiac events or deaths were reported in Pfizer's study of ritlecitinib, it is in this class of drugs. As a result, its future remains very uncertain. If the JAK inhibitor class ultimately withstands increased regulatory scrutiny and the efficacy of ritlecitinib safely treating alopecia persists, the drug could provide a reliable revenue stream for Pfizer. To support this thesis, let's take a look at the global alopecia market and its growth forecast. Pointing to the "increasing prevalence of hair loss" as well as "technological advances in alopecia treatment," Grand View Research believes that the total global alopecia market will grow at an annual rate of 8.1% from $7.6 billion in 2020 to $14.2 billion by 2028. If the alopecia market stays at 35.2% of the total global alopecia market as it was in 2020, Pfizer's total addressable market in this area will be $5 billion by 2028. Given that Pfizer will likely face competition from Concert Pharmaceuticals' JAK inhibitor CTP-543 (first Phase 3 results not expected until 2022) and Eli Lilly and Incyte's JAK inhibitor baricitinib (currently awaiting FDA decision) when it enters the alopecia market, a fragmented market share of 15% is realistic. This would result in $750 million in annual revenue associated with the alopecia drug indications by 2028, which is about 1% of Pfizer's projected 2021 revenue of $78-80 billion. As questions arise about whether JAK inhibitors such as ritlecitinib will be able to gain regulatory approval in the future, it is worth noting that Pfizer does not significantly necessitate that approval to boost earnings in the coming years. In addition to the BNT162b2 COVID-19 vaccine, developed with German company BioNTech, Pfizer also expects to be able to apply for approval in the fourth quarter of this year for the emergency use of the oral antiviral drug COVID-19, known as PF-07321332. Keith Speights thinks this could be a real blockbuster given the huge addressable market, especially since Pfizer won't have to share the profits from oral therapy as it does with BioNTech in the case of BNT162b2. In addition to COVID-19, Pfizer's oncology biosimilars (Ruxience, Zirabev, and Retacrit) tripled their combined sales from $107 million in the second quarter of 2020 to $352 million in the second quarter of 2021, another good catalyst for growth going forward. Nearly half of Pfizer's projected sales this year will come from the $33.5 billion the company expects from its BNT162b2 COVID-19 vaccine (after splitting revenue with a partner, BioNTech). This is based on the 2.1 billion doses the company estimates will be delivered this year. Given sales of the breast cancer drug Ibrance ($1.4 billion through Q2 2021) and the anticoagulant Eliquis ($1.5 billion through Q2 2021), we can assume that these two drugs will also bring in about $3 billion each.
NYSE:PFELong
by FOREXN1
6
PFE (PFIZER) At A crucial Breakout LevelTraders, PFE (PFIZER) has risen to the a crucial level. Watch out for the move down. However a breakout above from this level can take this to 49/50 price and even higher. Rules: 1. Never trade too much 2. Never trade without a confirmation 3. Never rely on signals, do your own analysis and research too ✅ If you found this idea useful, hit the like button, subscribe and share it in other trading forums. ✅ Follow me for future ideas, trade set ups and the updates of this analysis ✅ Don't hesitate to share your ideas, comments, opinions and questions. Take care and trade well -Vik ____________________________________________________ 📌 DISCLAIMER The content on this analysis is subject to change at any time without notice, and is provided for the sole purpose of education only. Not a financial advice or signal. Please make your own independent investment decisions. ____________________________________________________
NYSE:PFE
by vikinsa
3
Are Covid Stocks Coming Back?If there is any hope for the S&P right now it may very well come from the healthcare sector with mega blue chip Johnson & Johnson. JNJ has managed to put in consecutive higher highs and higher lows on the weekly, and now also is confirming support on the .618 fibonacci level at $165.40. However, there appears to still be much selling pressure at just above $168, so don't be surprised if we continue to see consolidation for another a week or two before getting the confirmed breakout above our red resistance line at the aforementioned $168 price level. If resistance at this level is broken, we will be seeing a possible retest of blue sky all time highs for the healthcare giant JNJ. In the meantime, I am liking the idea of small longs along the .618 ($165.40) area as long as the upward sloping green trend is not violated.
NYSE:JNJLong
by TradeVibez
PFE Pfizer short term Price TargetWith the new Covid-19 Delta Variant which is more contagious than the other virus strains the question is if you want to get vaccinated or get COVID-19. PFE Pfizer has a great vaccine, a decent P/E Ratio (TTM) of 20.34, pays Forward Dividend & Yield of 1.56 (3.89%) and it is not at all time high like MRNA for example. Expected sales from vaccine in 2021: $15bn-$30bn My short term price target is 44usd. i`m looking forward to read your opinion about it.
NYSE:PFELong
by TopgOptions
6